Pauwels Eric, chief business officer of PTC Therapeutics (PTCT), has been a consistent seller of company stock over the past year, with no open-market purchases on record. Across 54 Form 4 filings, he has disposed of approximately $9.73 million in shares, all in PTCT. The most recent activity, clustered in June 2026, shows three sales totaling roughly $1.9 million on June 10, paired with an option exercise valued at about $316,000. That pattern—exercising options and immediately selling the underlying shares—repeats throughout his filing history, including a December 19, 2025 exercise of $1.3 million alongside eight sales that day worth nearly $1.6 million.
The selling bias is unambiguous: 19 open-market sales in the recent window versus zero purchases. Individual transactions range from small dispositions of a few thousand dollars to block sales exceeding $800,000, such as the December 19, 2025 sale of $817,997.40. The filings also include routine compensation events—two zero-value grants on January 2, 2026—and tax-withholding transactions, which are automatic and not discretionary. Pauwels has not acquired shares through open-market buys at any point in the data, meaning every acquisition stems from option exercises or awards, and nearly all resulting shares have been sold promptly.
The concentration in a single ticker and the steady cadence of sales—spanning January, February, June, and December of the covered period—suggest a systematic approach to monetizing equity compensation rather than opportunistic timing. The largest dollar volumes cluster around option exercise dates, consistent with a sell-to-cover or cash-out strategy. While the data cannot speak to intent, the record is clear: Pauwels has been a net seller of PTCT stock throughout, with no countervailing purchases to signal conviction in the company’s valuation.
AI-assisted summary